Biochimica et biophysica acta. Reviews on cancer最新文献_第9页

EV-mediated asymmetrical crosstalk between CAFs and cancer cells in the tumor microenvironment 肿瘤微环境中由ev介导的CAFs与癌细胞之间的不对称串扰。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-07-03 DOI: 10.1016/j.bbcan.2025.189380

Alice Santi, Annalisa Moccia, Anna Caselli, Paolo Cirri

{"title":"EV-mediated asymmetrical crosstalk between CAFs and cancer cells in the tumor microenvironment","authors":"Alice Santi, Annalisa Moccia, Anna Caselli, Paolo Cirri","doi":"10.1016/j.bbcan.2025.189380","DOIUrl":"10.1016/j.bbcan.2025.189380","url":null,"abstract":"<div><div>Tumor is a complex tissue composed of both genetically transformed cancer cells and the cells of the tumor microenvironment, including connective cells, immune cells, and endothelial cells that actively contribute to the maintenance of the tumor and, consequently, to its progression. As for any other tissue, the communication between cells of the tumor microenvironment plays an essential role in determining the architecture and physiology of the tumor tissue. This intercellular communication is classically mediated by soluble factors (such as cytokines and growth factors) but it has been shown that the extracellular vesicle (EV) trafficking may also contribute to tumor growth and progression. In this paper, we discuss the EV-mediated transfer of proteins between cancer cells and cancer-associated fibroblasts (CAFs) in an attempt to propose an interpretation of the relationships between these two cell types within the tumor microenvironment. In particular, we propose that this type of crosstalk between cancer cells and CAFs is asymmetrical: on the one hand, cancer cells secrete signaling protein-bearing exosomes that induce the trans-differentiation of neighboring fibroblasts into CAFs; on the other hand, CAFs transfer biomass to cancer cells through ectosome trafficking, thus supporting cancer cell proliferation.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 4","pages":"Article 189380"},"PeriodicalIF":9.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combination therapy in cancer: The potential of tetrandrine as a polytherapy for acute myeloid leukemia 癌症的联合治疗：粉防己碱作为急性髓性白血病的综合治疗的潜力

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-06-26 DOI: 10.1016/j.bbcan.2025.189377

Daniel L. Barry , Anoop K. Enjeti , Lisa F. Lincz , Kathryn A. Skelding

{"title":"Combination therapy in cancer: The potential of tetrandrine as a polytherapy for acute myeloid leukemia","authors":"Daniel L. Barry , Anoop K. Enjeti , Lisa F. Lincz , Kathryn A. Skelding","doi":"10.1016/j.bbcan.2025.189377","DOIUrl":"10.1016/j.bbcan.2025.189377","url":null,"abstract":"<div><div>Acute Myeloid Leukemia (AML) is the most common form of leukemia diagnosed in adults with the lowest survival rates. It is a heterogeneous disease and incidence rates increase yearly, with the overall survival of AML patients remaining low. Emerging treatment strategies are key in improving the recovery rates of those diagnosed with AML due to not all patients responding to currently used intense chemotherapeutics. For the best treatment of AML patients possible, new treatments must be developed and treatment biomarkers identified.</div><div>Tetrandrine is a calcium channel blocker that is a potential treatment. It has demonstrated anti-proliferation, pro-autophagic and apoptotic, and multidrug resistance reversal effects on solid cancer varieties, thought to be potentiated by acquired genomic abnormalities, and it is hypothesised that it could be repurposed to act in a similar role in haematological cancers, namely AML. Although research into the effects of tetrandrine in AML is limited, the genomic abnormalities within subsets of the disease may reveal patients that would benefit from tetrandrine treatment.</div><div>This review aims to explore the potential mechanisms of tetrandrine treatment in AML, drawing on information gained through tetrandrine treatment in solid cancer. The main focus will be interactions with genes, protein, and pathways commonly dysregulated in AML, namely Tumour Protein 53 (TP53), C-Myc (MYC), Kirsten Rate Sarcoma Virus (KRAS), Vascular Endothelial Growth Factor (VEGF), Fms-like tyrosine kinase 3 (FLT3) and Nuclear Receptor Subfamily 4A1 (NR4A1) as well as the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3)-inflammasome and calcium–calmodulin (CaM)-dependent protein kinase II (CaMKII).</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 4","pages":"Article 189377"},"PeriodicalIF":9.7,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144523185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meet PRC2: A new player in T-cell acute lymphoblastic leukemia 认识PRC2: t细胞急性淋巴细胞白血病的新参与者。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-06-19 DOI: 10.1016/j.bbcan.2025.189376

Raquel Monteiro de Barros Lemos , Marina Chianello Nicolau Fagundes , Ana Luiza Tardem Maciel , Mariana Emerenciano

引用次数: 0

Exploring synthetic lethality in cancer therapy: CRISPR-Cas9 technology offers new hope 探索癌症治疗中的合成致死性：CRISPR-Cas9技术带来了新的希望

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-06-13 DOI: 10.1016/j.bbcan.2025.189370

Yuqi Wu, Yali Wang, Yanbin Wang, Hong Qiu, Xianglin Yuan, Hua Xiong, Yanmei Zou

{"title":"Exploring synthetic lethality in cancer therapy: CRISPR-Cas9 technology offers new hope","authors":"Yuqi Wu, Yali Wang, Yanbin Wang, Hong Qiu, Xianglin Yuan, Hua Xiong, Yanmei Zou","doi":"10.1016/j.bbcan.2025.189370","DOIUrl":"10.1016/j.bbcan.2025.189370","url":null,"abstract":"<div><div>Synthetic lethality (SL) is a breakthrough concept in cancer therapy that describes a scenario in which the simultaneous inactivation of two genes leads to cell death, whereas inactivation of either gene alone does not. The rise of clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated nuclease 9 (Cas9) technology has provided a new tool for exploring this phenomenon, enabling genome editing and screening. This review evaluates the advancements achieved by CRISPR technology in identifying novel therapeutic targets and comprehending the processes of drug resistance using the concept of SL in cancer cells. This review explores the fundamental concept of SL and its application in cancer therapy, highlighting how the CRISPR-Cas9 system functions and how CRISPR-based screening can be leveraged to identify synthetic lethal genes and investigate the mechanisms of drug resistance. We summarize important research in related fields from recent years, demonstrating the role of CRISPR screening in revealing cancer cellular pathways and identifying new drug targets. We also summarize the clinical trials of related drugs currently underway, and anticipate that with the continuous development of CRISPR technology, its integration with cancer genetics and immuno-oncology will bring new hope to patients with drug-resistant cancers.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 4","pages":"Article 189370"},"PeriodicalIF":9.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144288805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance 卵巢癌中的VEGF/VEGFR2系统：从功能到药理意义

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-06-12 DOI: 10.1016/j.bbcan.2025.189374

Elisabetta Grillo , Chiara Romani , Victoria M. Ettorre , Alessandro D. Santin , Stefania Mitola

{"title":"The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance","authors":"Elisabetta Grillo , Chiara Romani , Victoria M. Ettorre , Alessandro D. Santin , Stefania Mitola","doi":"10.1016/j.bbcan.2025.189374","DOIUrl":"10.1016/j.bbcan.2025.189374","url":null,"abstract":"<div><div>The vascular endothelial growth factor receptor 2 (VEGFR2) is a tyrosine kinase receptor regulating a variety of biological processes, including embryonic development, angiogenesis, tissue homeostasis and cancer. VEGFR2 is activated by canonical VEGFs and non-canonical ligands, triggering intracellular signaling cascades that mediate its biological activity. Preclinical studies show that VEGFR2 plays a complex yet pivotal role in the progression of ovarian cancer (OC), a deadly disease with a global burden of more than 320,000 women in 2022. Several inhibitors of the VEGF/VEGFR2 axis have been developed and are currently approved or included in clinical trials/preclinical studies for the therapy of different subtypes of OC. Originally developed as anti-angiogenics, anti-VEGF/VEGFR2 drugs are now well-known to also affect tumor cells, immune cells and cancer-associated fibroblasts (CAFs), also in OC. In this review we address the specific role of the VEGF/VEGFR2 axis in OC cells, and, from this perspective, we discuss the therapeutic significance of VEGFR2 targeting. Dissection of the molecular landscape modulated by the VEGF/VEGFR2 system in tumor cells in addition to stromal ones will facilitate ongoing translational efforts directed toward OC therapy.</div></div><div><h3>Significance statement</h3><div>Anti-angiogenics blocking the VEGF/VEGFR2 axis are widely used to treat ovarian cancer, although resistance and poor response occur. Recent advances reveal that anti-VEGF/VEGFR2 drugs act on multiple compartments, including ovarian cancer cells. This review discusses the functional and pharmacological significance of the VEGF/VEGFR2 axis in ovarian cancer cells highlighting insights from preclinical and clinical studies. A deeper understanding of this pathway is essential for a safe/efficacious usage of anti-angiogenics targeting the VEGFR2 pathway in ovarian cancer.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 4","pages":"Article 189374"},"PeriodicalIF":9.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-06-12 DOI: 10.1016/j.bbcan.2025.189375

Jiaying Xiong , Xin Wen , Meiyan Chen , Fang Liu , Jueyu Zhou

{"title":"Autophagy-related myosins: Critical roles and potential therapeutic effects in malignancies","authors":"Jiaying Xiong , Xin Wen , Meiyan Chen , Fang Liu , Jueyu Zhou","doi":"10.1016/j.bbcan.2025.189375","DOIUrl":"10.1016/j.bbcan.2025.189375","url":null,"abstract":"<div><div>Myosins, a superfamily of actin-based molecular motor proteins, are important regulators of actin cytoskeleton structure and remodeling. They act as mechano-sensors of the tumor environment, controlling key cellular processes associated with tumorigenesis and mediating various cellular activities, including muscle contraction, cell migration, intracellular transport, membrane protrusion formation, cell adhesion, and cell signaling. In eukaryotic cells, autophagy plays a crucial role in maintaining cellular homeostasis by transporting cytoplasmic cargo to lysosomes for selective degradation. In tumors, recent research has explored the function of the role of myosin-influenced autophagy and tumor microenvironment-associated immune cells. Increasing evidence exists on how myosins and their mediated autophagy-related processes affect cancer development and progression. In this review, we discuss and dissect the functions played by different myosins at various stages of autophagy, and how myosins mediate autophagy involvement in the tumor process, based on the summaries of these findings, we provide new perspectives for possible therapeutic strategies.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 4","pages":"Article 189375"},"PeriodicalIF":9.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lactate metabolism reprogramming in PDAC: Potential for tumor therapy PDAC中乳酸代谢重编程：肿瘤治疗的潜力。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-06-11 DOI: 10.1016/j.bbcan.2025.189373

Fan Gao , Kang Sun , Sicheng Wang , Xiaozhen Zhang , Xueli Bai

引用次数: 0

Unveiling the TGF-β/Smad signaling in renal carcinoma progression: Prognostic and therapeutic insights 揭示肾癌进展中TGF-β/Smad信号：预后和治疗见解

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-06-10 DOI: 10.1016/j.bbcan.2025.189372

Vânia Dias , Ângela Alves , Rui Medeiros , Ana Luísa Teixeira , Francisca Dias

{"title":"Unveiling the TGF-β/Smad signaling in renal carcinoma progression: Prognostic and therapeutic insights","authors":"Vânia Dias , Ângela Alves , Rui Medeiros , Ana Luísa Teixeira , Francisca Dias","doi":"10.1016/j.bbcan.2025.189372","DOIUrl":"10.1016/j.bbcan.2025.189372","url":null,"abstract":"<div><div>About 2 to 3 % of all new cancer cases worldwide are renal carcinomas. Nevertheless, during the past few decades, there has been a 2 % annual increase in the prevalence of this malignancy worldwide. Within three years, 20 to 40 % of individuals with early-stage malignancies may either have a local recurrence or metastasis, and 20 to 30 % will receive a diagnosis of metastatic illness. For renal cancer, traditional chemotherapy and radiation are ineffective, while metastatic-focused treatments are linked to several side effects and the quick emergence of resistance. As a silent disease with no specific and identifiable signs and symptoms and an aggressive nature, there is an urgent need to discover trustworthy prognostic biomarkers as well as novel therapeutic targets. With multiple studies suggesting that renal carcinoma is a disease with complex genomic and epigenomic backgrounds influencing tumor development and progression, it is essential to study the dysregulated cellular pathways behind this disease to address this need. In this context, the canonical TGF-β signaling pathway could reveal interesting clues. The current study attempts to outline the role of this signaling mechanism in renal cancer dynamics, with a focus on its potential prognostic, predictive, and therapeutic relevance.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 4","pages":"Article 189372"},"PeriodicalIF":9.7,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144270717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The NLRP3 inflammasome and its role in acute myeloid leukemia onset and development NLRP3炎性小体及其在急性髓性白血病发生和发展中的作用。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-06-09 DOI: 10.1016/j.bbcan.2025.189371

Brunno Gilberto Santos de Macedo , Manuela Albuquerque de Melo , Diego Antonio Pereira-Martins , João Agostinho Machado-Neto , Fabiola Traina

引用次数: 0

Deciphering ETS2: An indispensable conduit to cancer 解读ETS2：癌症不可缺少的通道。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-06-07 DOI: 10.1016/j.bbcan.2025.189368

Samu John , Dhanya Kalathil , Ramesh Pothuraju , Sivakumari Asha Nair

{"title":"Deciphering ETS2: An indispensable conduit to cancer","authors":"Samu John , Dhanya Kalathil , Ramesh Pothuraju , Sivakumari Asha Nair","doi":"10.1016/j.bbcan.2025.189368","DOIUrl":"10.1016/j.bbcan.2025.189368","url":null,"abstract":"<div><div>E26 Transformation-Specific homolog 2 (ETS2) is a founding member of the ETS family of transcription factors and has been implicated in several developmental and survival functions. The predominant route of its action is by directly binding and regulating the promoters of its target genes, although it can function through other regulatory mechanisms as well. In this review, a comprehensive understanding of the contribution of ETS2 in health and disease is described with specific focus on cancer. ETS2 demonstrates extreme complexity as it can act as a double-edged sword in cancer with tumour suppressive or oncogenic functions in a context specific manner. Here, we delineate the different signalling pathways, post-translational modifications, miRNA regulations and protein-protein interactions that illustrate the role of ETS2 as an emerging biomarker with special emphasis on its contribution to ‘hallmarks of cancer’. Given the evidently opposing effects of ETS2 in different cancers, elucidating the critical mechanisms in its development and progression can validate ETS2's potential as a novel therapeutic target. Finally, we provide insights into frontier areas of research focus that implicate ETS2 and can translate into clinical outcomes.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 4","pages":"Article 189368"},"PeriodicalIF":9.7,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0